Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inactivated UPEC-FimON in NMIUC
NCT07881666Phase 1Recruiting
- Sponsor
- Hopec Pharma
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of UPEC-FimON in non-muscle invasive urothelial carcinoma (NMIBC) (4 cohorts), sponsored by Hopec Pharma. Primary endpoint: Safety and Tolerability of Inactivated UPEC-FimON at 14 weeks. Started Oct 2025; status: recruiting.
02
Drugs
UPEC-FimON
03
Conditions
non-muscle invasive urothelial carcinoma (NMIBC)
Beyond the preview
Go deeper on NCT07881666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881666.